Search

Displaying results 4861 - 4870 of 5261 in total
  1. Drug

    D-Tryptophan

    go.drugbank.com/drugs/DB03225
    Experimental

    It is an essential amino acid as defined by its growth effects on rats.

  2. Drug

    Ciclopirox

    go.drugbank.com/drugs/DB01188
    ApprovedInvestigational

    Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses. In particular, the agent is especially effective ...

  3. Drug

    Becatecarin

    go.drugbank.com/drugs/DB06362
    Investigational

    Becatecarin is a derivative of rebeccamycin.

  4. Drug

    NLX-P101

    go.drugbank.com/drugs/DB05924
    Experimental

    NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease.

  5. Drug

    AG0301-COVID19

    go.drugbank.com/drugs/DB15856
    Investigational

    AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University.

  6. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.

  7. Drug

    Quinapril

    go.drugbank.com/drugs/DB00881
    ApprovedInvestigational

    Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat. It is used to treat hypertension and heart failure. ACE inhibitors are commonly used as a first line therapy in the treatment...

  8. Drug

    Ambenonium

    go.drugbank.com/drugs/DB01122
    ApprovedWithdrawn

    Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.

  9. Drug

    Tenapanor

    go.drugbank.com/drugs/DB11761
    ApprovedInvestigational

    Tenapanor is a novel, small molecule medication approved in September 2019 for the treatment of constipation-predominant irritable bowel-syndrome (IBS-C). It was first designed and synthesized in 2012. As an inhibitor of the sodium/hydro...

  10. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    Zanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). It has been investigated for the treatment of HER2-positive solid tumors, including gastroesophageal, colorectal, and biliary tract cancers. In No...